Study #2020-1155
A PHASE IIA STUDY EVALUATING THE PHARMACOKINETICS, SAFETY AND EFFICACY OF APG-115 AS A SINGLE AGENT OR IN COMBINATION WITH APG-2575 IN SUBJECTS WITH RELAPSED/REFRACTORY T-CELL PROLYMPHOCYTIC LEUKEMIA (R/R T-PLL)
MD Anderson Study Status
Enrolling
Treatment Agent
APG-115, APG-2575
Description
The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma
Study phase:
Phase II
Physician name:
Tapan Kadia
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.